Hepabio is dedicated to the development and application of advanced 3D microtissue platforms, delivering robust safety, efficacy, and metabolic evaluations to support preclinical drug development. Our founding team originates from the Karolinska Institute, home to the Nobel Assembly for the Nobel Prize in Physiology or Medicine. We have partnered with more than sixty leading pharmaceutical companies worldwide, providing industry-trusted preclinical evaluation solutions that accelerate innovative drug development.

Shanghai HepaBiotech

Org chart

Teams

Offices